Clearside Biomedical, Inc. 8-K Filing

Ticker: CLSDQ · Form: 8-K · Filed: Oct 9, 2024 · CIK: 1539029

Clearside Biomedical, Inc. 8-K Filing Summary
FieldDetail
CompanyClearside Biomedical, Inc. (CLSDQ)
Form Type8-K
Filed DateOct 9, 2024
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Clearside Biomedical, Inc. (ticker: CLSDQ) to the SEC on Oct 9, 2024.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (ch registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Mar).

How long is this filing?

Clearside Biomedical, Inc.'s 8-K filing is 2 pages with approximately 623 words. Estimated reading time is 2 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 623 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-10-09 07:55:13

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Mar

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 9, 2024, Clearside Biomedical, Inc. (the " Company ") will give a presentation describing its positive topline results from ODYSSEY, the Company's Phase 2b clinical trial of CLS-AX for the treatment of wet AMD. The live and archived webcast may be accessed on the Company's website under the "Investors" section. A copy of the presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in, or that can be accessed through, the Company's website is not a part of this filing. The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On October 9, 2024, the Company issued a press release announcing the topline results from the ODYSSEY Phase 2b clinical trial. The full text of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Corporate Presentation, dated October 9, 2024. 99.2 Press Release, dated October 9, 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Clearside Biomedical, Inc. Date: October 9, 2024 By: /s/ Charles A. Deignan Charles A. Deignan Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.